{
  "catalogId": "72879d3c-cd1b-4502-a6a5-c6cc190b06a1",
  "name": "DIFLUCAN 50 MG/5 ML",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "106 79 29073 00",
  "treatmentDescriptions": "Fluconazole is indicated in the following fungal infections.Fluconazole is indicated in adults for the treatment of:•\tCryptococcal meningitis.•\tCoccidioidomycosis.•\tInvasive candidiasis.•\tMucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.•\tChronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.•\tVaginal candidiasis, acute or recurrent; when local therapy is not appropriate.•\tCandidal balanitis when local therapy is not appropriate.•\tDermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.•\tTinea unguinium (onychomycosis) when other agents are not considered appropriate.Fluconazole is indicated in adults for the prophylaxis of:•\tRelapse of cryptococcal meningitis in patients with high risk of recurrence.•\tRelapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.•\tTo reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).•\tProphylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation).Fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.  Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.Consideration should be given to official guidance on the appropriate use of antifungals.",
  "termsOfIssue": "Prescription required",
  "form": "powder for oral suspension",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "FLUCONAZOLE/",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "J02AC01",
      "name": "FLUCONAZOLE"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "DIFLUCAN SUSP 50MG/5ML 35ML",
      "manufacturer": {
        "name": "פיזר",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 35.0,
        "unit": "units"
      },
      "packagingDescription": "BOTTLE HDPE",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "3624",
        "yarpa": "76478",
        "pharmasoft": "4182",
        "barcode": "7290008094153"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 31.05409253,
        "retailMargin": 37.0,
        "maxRetailPrice": 42.54410677,
        "maxPriceWithVAT": 50.20204376
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:43.591876"
  }
}